70 related articles for article (PubMed ID: 33379361)
1. Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma.
Molavi O; Xiong XB; Douglas D; Kneteman N; Nagata S; Pastan I; Chu Q; Lavasanifar A; Lai R
Biomaterials; 2013 Nov; 34(34):8718-8725. PubMed ID: 23942212
[TBL] [Abstract][Full Text] [Related]
2. Encapsulated Checkpoint Blocker Before Chemotherapy: The Optimal Sequence of Anti-CTLA-4 and Doxil Combination Therapy.
Alimohammadi R; Alibeigi R; Nikpoor AR; Chalbatani GM; Webster TJ; Jaafari MR; Jalali SA
Int J Nanomedicine; 2020; 15():5279-5288. PubMed ID: 32801691
[TBL] [Abstract][Full Text] [Related]
3. TXB-001, a newly-developed polymer-conjugated anthracycline: Significantly lower adverse effects in animal models of alopecia and hand-foot syndrome.
Hirakata M; Tomikawa E; Sakai C; Uchida M; Okano T; Shimozono R; Kawai M; Itaba S; Munakata L; Suzuki R; Oshida K
Toxicol Appl Pharmacol; 2024 Apr; 485():116912. PubMed ID: 38521368
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effect of MCC-465, pegylated liposomal doxorubicin tagged with newly developed monoclonal antibody GAH, in colorectal cancer xenografts.
Hamaguchi T; Matsumura Y; Nakanishi Y; Muro K; Yamada Y; Shimada Y; Shirao K; Niki H; Hosokawa S; Tagawa T; Kakizoe T
Cancer Sci; 2004 Jul; 95(7):608-13. PubMed ID: 15245599
[TBL] [Abstract][Full Text] [Related]
5. Understanding the In Vitro-In Vivo Nexus: Advanced correlation models predict clinical performance of liposomal doxorubicin.
Gan K; Li Z; Darli PM; Wong T; Modh H; Gottier P; Halbherr S; Wacker MG
Int J Pharm; 2024 Apr; 654():123942. PubMed ID: 38403086
[TBL] [Abstract][Full Text] [Related]
6. Iron-crosslinked Rososome with robust stability and high drug loading for synergistic cancer therapy.
Xue X; Ricci M; Qu H; Lindstrom A; Zhang D; Wu H; Lin TY; Li Y
J Control Release; 2021 Jan; 329():794-804. PubMed ID: 33039481
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in Ovarian Cancer: Towards Personalized Medicine.
López-Portugués C; Montes-Bayón M; Díez P
Proteomes; 2024 Mar; 12(1):. PubMed ID: 38535506
[TBL] [Abstract][Full Text] [Related]
8. Lipid-Based Nanoparticle Functionalization with Coiled-Coil Peptides for
Aschmann D; Knol RA; Kros A
Acc Chem Res; 2024 Apr; 57(8):1098-1110. PubMed ID: 38530194
[TBL] [Abstract][Full Text] [Related]
9. The role of peptides in reversing chemoresistance of breast cancer: current facts and future prospects.
Huang Y; Peng H; Zeng A; Song L
Front Pharmacol; 2023; 14():1188477. PubMed ID: 37284316
[TBL] [Abstract][Full Text] [Related]
10. Recent Preclinical and Clinical Progress in Liposomal Doxorubicin.
Aloss K; Hamar P
Pharmaceutics; 2023 Mar; 15(3):. PubMed ID: 36986754
[TBL] [Abstract][Full Text] [Related]
11. A multicenter randomized trials to compare the bioequivalence and safety of a generic doxorubicin hydrochloride liposome injection with Caelyx
Li Y; Qi L; Wang Y; Li Y; Lei C; Zhang Y; Cheng X; Liu J; Bai H; Zhao X; Lv S; Xiong B; Liu J; Shi Y; Zhou H; Li H; Liu L; Jiang H; Ouyang W; Li X; Li Y; Wang X
Front Oncol; 2022; 12():1070001. PubMed ID: 36605440
[TBL] [Abstract][Full Text] [Related]
12. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
Aldughaim MS; Alsaffar F; Barker MD
Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
[TBL] [Abstract][Full Text] [Related]
13. Liposomal formulation of Galbanic acid improved therapeutic efficacy of pegylated liposomal Doxorubicin in mouse colon carcinoma.
Nik ME; Malaekeh-Nikouei B; Amin M; Hatamipour M; Teymouri M; Sadeghnia HR; Iranshahi M; Jaafari MR
Sci Rep; 2019 Jul; 9(1):9527. PubMed ID: 31267009
[TBL] [Abstract][Full Text] [Related]
14. Targeting CD44 expressing cancer cells with anti-CD44 monoclonal antibody improves cellular uptake and antitumor efficacy of liposomal doxorubicin.
Arabi L; Badiee A; Mosaffa F; Jaafari MR
J Control Release; 2015 Dec; 220(Pt A):275-286. PubMed ID: 26518722
[TBL] [Abstract][Full Text] [Related]
15. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies.
Gabizon A; Shmeeda H; Barenholz Y
Clin Pharmacokinet; 2003; 42(5):419-36. PubMed ID: 12739982
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin as targeted delivery platform: Current trends in surface functionalization.
Makwana V; Karanjia J; Haselhorst T; Anoopkumar-Dukie S; Rudrawar S
Int J Pharm; 2021 Jan; 593():120117. PubMed ID: 33259901
[TBL] [Abstract][Full Text] [Related]
18. Specific Targeting of PEGylated Liposomal Doxorubicin (Doxil
Aldughaim MS; Muthana M; Alsaffar F; Barker MD
Molecules; 2020 Dec; 26(1):. PubMed ID: 33379361
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
